ATTR Webinar, March 19, 2022

ASG Webinar on ATTR Amyloidosis, March 19, 2022

This video is from a live webinar. It has been slightly edited for content, clarity, and time.

Presenters and Panelists
Muriel Finkel, President, Amyloidosis Support Groups
Paula Schmitt, Executive Director, Amyloidosis Support Groups
Mathew S. Maurer, MD, Cardiologist, Director, Cardiac Amyloidosis Center, Professor of Medicine, Columbia University Medical Center
Nitasha Sarswat, MD, Director of Infiltrative Cardiomyopathy Program, University of Chicago Medicine
Lynn Punnoose, MD, Director, Vanderbilt Advanced Heart Failure/Transplant Fellowship Program, Vanderbilt University Medical Center
Sami Khella, MD, Chief of Neurology, Penn Presbyterian Medical Center
Michael Maitland, MD, PhD, Sr. Director, Clinical Development, Intellia Therapeutics
*Colleen Moffitt, PharmD, MS, US ATTR Medical Director, Alnylam Pharmaceuticals
Gustavo Buchele, MD, PhD, Executive Director, Clinical Development, Ionis Pharmaceuticals
*Abbas Ebrahim, MD, Sr. Medical Director, US Medical Affairs, Rare Disease, Pfizer
*Lori Baylor, PhD, Medical Director, Rare Cardiology, US Medical Affairs, Rare Disease, Pfizer
Spencer Guthrie, Cofounder & Chief Operating Officer, Attralus, Inc., South San Francisco, CA

Chapters
0:00 Introduction of Speakers
2:50 ATTR Treatment Chart
3:34 Webinar attendee poll on Sleep Apnea
5:15 Dr. Mat Maurer, Overview of ATTR and Cardiomyopathy
20:10 Q&A Session 1
36:10 Dr. Sami Khella, Neuropathy and ATTR
55:29 ASG information request on home infusions through Medicare
56:29 Q&A Session 2
1:19:36 Paula Schmitt, Financial Assistance
1:27:13 Dr. Sami Khella on Carpal Tunnel
1:30:23 Dr. Michael Maitland, Update on Intellia’s CRISPR/Cas9 Genome Editing for ATTR
1:41:56 Dr. Gustavo Buchele, Update on Ionis’s TTRansform Program (Eplontersen)
1:50:28 Spencer Guthrie, Update on Attralus’s amyloidosis imaging and therapeutic agents
2:03:05 Q&A Session 3

*Presentations made by Alnylam and Pfizer during the webinar are not yet authorized for publication on YouTube. When and if authorized, ASG will make those presentations available on this YouTube channel.